PL1603544T3 - Leczenie stanów żołądkowo-jelitowych za pomocą N-2,3,3-tertametylobicyklo2.2.1 heptano-2-aminy - Google Patents

Leczenie stanów żołądkowo-jelitowych za pomocą N-2,3,3-tertametylobicyklo2.2.1 heptano-2-aminy

Info

Publication number
PL1603544T3
PL1603544T3 PL04720110T PL04720110T PL1603544T3 PL 1603544 T3 PL1603544 T3 PL 1603544T3 PL 04720110 T PL04720110 T PL 04720110T PL 04720110 T PL04720110 T PL 04720110T PL 1603544 T3 PL1603544 T3 PL 1603544T3
Authority
PL
Poland
Prior art keywords
tetramethylbicyclo
heptan
amine
treatment
intestinal conditions
Prior art date
Application number
PL04720110T
Other languages
English (en)
Inventor
John Devane
Original Assignee
Agi Therapeutics Res Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Res Limited filed Critical Agi Therapeutics Res Limited
Publication of PL1603544T3 publication Critical patent/PL1603544T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL04720110T 2003-03-14 2004-03-12 Leczenie stanów żołądkowo-jelitowych za pomocą N-2,3,3-tertametylobicyklo2.2.1 heptano-2-aminy PL1603544T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45452703P 2003-03-14 2003-03-14
PCT/IB2004/001134 WO2004080446A1 (en) 2003-03-14 2004-03-12 Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
EP04720110A EP1603544B1 (en) 2003-03-14 2004-03-12 Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo 2.2.1 heptan-2-amine

Publications (1)

Publication Number Publication Date
PL1603544T3 true PL1603544T3 (pl) 2008-03-31

Family

ID=32990912

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04720110T PL1603544T3 (pl) 2003-03-14 2004-03-12 Leczenie stanów żołądkowo-jelitowych za pomocą N-2,3,3-tertametylobicyklo2.2.1 heptano-2-aminy

Country Status (17)

Country Link
US (1) US20040209961A1 (pl)
EP (1) EP1603544B1 (pl)
JP (1) JP2006520379A (pl)
AT (1) ATE375152T1 (pl)
AU (1) AU2004218899A1 (pl)
CA (1) CA2518385A1 (pl)
CY (1) CY1108042T1 (pl)
DE (1) DE602004009414T2 (pl)
DK (1) DK1603544T3 (pl)
ES (1) ES2294480T3 (pl)
MX (1) MXPA05009640A (pl)
NO (1) NO20054670L (pl)
NZ (1) NZ542260A (pl)
PL (1) PL1603544T3 (pl)
PT (1) PT1603544E (pl)
WO (1) WO2004080446A1 (pl)
ZA (1) ZA200507159B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224284A1 (en) 2004-03-12 2007-09-27 John Devane Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof
US20060182819A1 (en) * 2005-02-17 2006-08-17 Ough Yon D Soap scent patch and treatment for muscle spasm and pain
US20060182818A1 (en) * 2005-02-17 2006-08-17 Ough Yon D Transdermal patch and treatment for pain and discomfort
US20070108228A1 (en) * 2005-11-15 2007-05-17 Willam Kleyne Method and apparatus for flushing eyes and skin
US20080207766A1 (en) * 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
US8569381B2 (en) 2008-05-23 2013-10-29 Targacept, Inc. Combination therapy for the management of hypertension
SG178987A1 (en) * 2009-09-29 2012-04-27 Novartis Ag Dosage regimen of an s1p receptor modulator
US8529914B2 (en) 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
CA3050082A1 (en) 2016-04-04 2017-10-12 Omeza LLC Fish oil topical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034079A (en) * 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
CN1155410C (zh) * 1997-10-03 2004-06-30 卡里药品公司 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
US6121289A (en) * 1998-10-09 2000-09-19 Theramax, Inc. Method for enhanced brain delivery of nicotinic antagonist
AU778992B2 (en) * 1998-12-07 2004-12-23 Agi Therapeutics Research Limited Transdermal patch for delivering volatile liquid drugs
EP1139743B1 (en) * 1998-12-16 2006-03-22 University Of South Florida Exo-s-mecamylamine formulation and use in treatment
US6734215B2 (en) * 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders

Also Published As

Publication number Publication date
MXPA05009640A (es) 2005-10-26
DK1603544T3 (da) 2008-01-14
DE602004009414D1 (de) 2007-11-22
DE602004009414T2 (de) 2008-07-24
AU2004218899A1 (en) 2004-09-23
EP1603544A1 (en) 2005-12-14
PT1603544E (pt) 2008-01-22
NZ542260A (en) 2009-03-31
ES2294480T3 (es) 2008-04-01
NO20054670L (no) 2005-12-13
CY1108042T1 (el) 2013-09-04
JP2006520379A (ja) 2006-09-07
CA2518385A1 (en) 2004-09-23
ATE375152T1 (de) 2007-10-15
WO2004080446A1 (en) 2004-09-23
EP1603544B1 (en) 2007-10-10
US20040209961A1 (en) 2004-10-21
NO20054670D0 (no) 2005-10-11
ZA200507159B (en) 2008-03-26
WO2004080446B1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
NO20054670L (no) Behandling av intestinale tilstander med N-2,3,3-tetrametylbisyklo[2.2.1]-heptan-2-amid
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
EP1581169A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO NATURAL K CELLS
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
WO2003101397A3 (en) Tetravalent dengue vaccines
SG150533A1 (en) 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
AU2003257937A8 (en) Methods and compositions for treatment of dermal conditions
MX249034B (es) Amidinas de tiofeno novedosas, composiciones de las mismas, y metodos para tratar enfermedades y condiciones mediadas por el complemento.
EP1670450A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING LEVODOPA AND CARBIDOPA
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
IL174627A0 (en) Compositions and methods for treatment of burns
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
EP1711197A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR DISORDERS
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
HK1088225A1 (en) Compositions comprising immunomodulatory compoundsfor treatment, modification and management of pai n
WO2003075953A3 (en) Immunomodulatory polymeric antigens for treating inflammatory pathogies
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
EP1651255A4 (en) TOPICAL VETERINARY COMPOSITIONS AND METHODS OF TREATING AND PREVENTING INFECTIONS
NO20054346D0 (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
NO20060420L (no) 2-aminobenzoylderivater
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
EP1546326A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSORIASIS
DE602004012759D1 (de) Behandlung von fibrosen